Nucala 100 MG/ML auto-injectorml
Ended Awarded Last action
- Contract number
- SPE2DR26FGVC7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,591
Award facts
- Contract value 100% obligated
- $11,590.98 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325411 Medicinal and Botanical Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $11,590.98 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for NUCALA 100 mg/ml auto-injector medication. The delivery order, issued on December 1, 2025, with an ultimate completion date of December 2, 2025, carries no set-aside designation, indicating the award was made through unrestricted competition. DMS Pharmaceutical Group is the sole awardee with no identified subcontractors on this transaction.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) designated SPE2DR, awarded November 13, 2025, under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The parent IDC carries a $499.999 billion ceiling value and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. As a regional prime vendor contractor within the $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group serves as a critical supplier of pharmaceuticals, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide. NUCALA, an immunosuppressant biologic agent, represents one component of the company's comprehensive pharmaceutical product portfolio supplied to federal agencies.
Quick answers
Who was awarded contract SPE2DR26FGVC7?
SPE2DR26FGVC7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 1, 2025.
How much is contract SPE2DR26FGVC7 worth?
The government has obligated $11,591 on SPE2DR26FGVC7.
Is contract SPE2DR26FGVC7 an order under another contract?
Yes. SPE2DR26FGVC7 is a delivery order under SPE2DR25D9761, an indefinite delivery contract.
Was contract SPE2DR26FGVC7 competed?
The extent of competition for SPE2DR26FGVC7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award